HER2/neu testing in primary colorectal carcinoma

BACKGROUND: Anti-HER2/neu therapy is well-established in breast and gastric carcinoma. The increased understanding of this pathway led to the identification of new promising drugs in addition to trastuzumab, offering further perspectives. The role of HER2/neu in colorectal carcinoma is controversial...

Descripción completa

Detalles Bibliográficos
Autores principales: Ingold Heppner, B, Behrens, H-M, Balschun, K, Haag, J, Krüger, S, Becker, T, Röcken, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229629/
https://www.ncbi.nlm.nih.gov/pubmed/25211663
http://dx.doi.org/10.1038/bjc.2014.483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229629/
https://www.ncbi.nlm.nih.gov/pubmed/25211663
http://dx.doi.org/10.1038/bjc.2014.483

Ejemplares similares